ClinicalTrials.gg
RecruitingNCT06958224ESCATUpdated Oct 22, 2026

Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers

An interventional study of Large and early multigene sequencing in Breast Cancer, Liver Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University Hospital, Lille · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 22, 2026Now RecruitingFirst site in France+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The European Society for Medical Oncology (ESMO) strongly recommends to develop multigene sequencing in the framework of molecular screening programmes, in order to improve access to innovative drugs and to accelerate clinical research in cancers.

  • Accordingly, this project aims to study the contribution of early systematic multigene sequencing (NGS) discussed in Molecular Tumour Board for poor prognosis cancers, with no current indication for early sequencing.
  • The investigators teams propose to perform a randomized study in tumours in which actionable therapeutic targets according to the ESMO ESCAT scale are known (ESCAT II/IV) especially in pancreatic ductal adenocarcinoma, hepatocellular carcinoma or triple negative breast cancer.

Two approaches will be compared: a large multigenic early sequencing approach since the first line setting versus a Plan France Medecine Genomique 2025 approach since the second line setting.

The frequency of really initiated therapeutic proposals according to the molecular status will be compared in each group.

Read the detailed description

Part 1 sequential multi-gene sequencing (Simple NGS),

  • Multi-gene DNA sequencing (43 genes panel corresponding to the most frequently targeted molecular alterations)
  • And if no contributive:

Part 2: randomized study between two sequential approaches

- Experimental arm: early Multi-gene DNA sequencing (638 genes panel) Multi-gene RNA sequencing (ARCHER panel)

  1. MMR status in molecular biology
  2. - Tumour Mutational Burden

    • Control arm: after 1st line escape, according to Plan France Medecine Genomique 2025 In the Part 2, a new biopsy could be proposed if necessary
02

Conditions studied

  • Breast Cancer
  • Liver Cancer
  • Pancreatic Ductal Adenocarcinoma

Keywords

  • Poor prognosis cancers
  • Multi-gene sequencing
  • Molecular Tumour Board
  • Personalized medicine
  • Clinical trials
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's planned enrollment of 360 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Age >18 years.
  • Advanced disease status ("unresectable" or "").
  • Patient included either at the time of diagnostic investigation or during of treatment.
  • Good general conditions, still compatible with a therapeutic proposal, WHO 0-1.
  • The following tumour sites, with poor prognosis and for which ESCAT II/IV treatment targets can be found according to ESMO:

    • pancreatic adenocarcinoma
    • hepatocellular carcinomas,
    • triple negative breast cancer.
  • Tumour tissue a priori available in sufficient quantity: at least one from a visceral metastatic site or surgical specimen (if available) for eligible cancers.
  • Patient covered by a social sercurity scheme

Exclusion criteria

Exclusion Criteria:

  • - General condition WHO >1 and/or nutritional status not compatible with a therapeutic proposal
  • Limiting systemic cardiovascular, renal, bronchopulmonary or endocrinological comorbidities with the initiation of a therapeutic proposal
  • Active infection or active chronic disease (diabetes, liver dysfunction, immune disease) making the patient's condition incompatible with a therapeutic proposal.
  • A priori unavailable, in insufficient quantity or of suboptimal quality tumour material.
  • Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security coverage, refusal to sign consent.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Large and early multigene sequencing

    Genetic: Large and early multigene sequencing

  • Active comparator
    Large Sequential multigene sequencing according to Plan France Medecine Genomique 2025

    Genetic: Large and early multigene sequencing

Interventions

  • GeneticLarge and early multigene sequencing

    Part 1 sequential multi-gene sequencing (Simple NGS), * Multi-gene DNA sequencing (43 genes panel corresponding to the most frequently targeted molecular alterations) * And if no contributive: Part 2: randomized study between two sequential approaches \- Experimental arm: early Multi-gene DNA sequencing (638 genes panel) Multi-gene RNA sequencing (ARCHER panel) 1. MMR status in molecular biology 2. \- Tumour Mutational Burden * Control arm: after 1st line escape, according to Plan France Medecine Genomique 2025 In the Part 2, a new biopsy could be proposed if necessary

06

What researchers measure

Primary outcomes

  1. Frequency of patients receiving a proposal for treatment leading to effective initiation of treatment.

    Time frame: Within 2 years of the first Molecular Tumour Board.

Secondary outcomes

  1. 1. Frequency of therapeutic proposals, whether or not leading to treatment, among patients with at least one molecular alteration found

    Time frame: Within 2 years of the first Molecular Tumour Board.

  2. 2. The number of potentially targetable molecular alterations found.

    Time frame: Within 2 years of the first Molecular Tumour Board.

  3. The frequency of the types of potentially targetable molecular alterations found according to the ESCAT classification (ESCAT I / II / III / IV).

    Time frame: Within 2 years of the first Molecular Tumour Board.

  4. 4. Frequency of types of therapeutic proposals (clinical trials, off-label targeted therapies).

    Time frame: Within 2 years of the first Molecular Tumour Board.

  5. Time to treatment proposal, defined as the time between the date of the first Molecular Tumour Board and the treatment proposal following the second Molecular Tumour Board.

    Time frame: Within 2 years of the first Molecular Tumour Board.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2028, 30 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 30 months is close to that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
May 6, 2025
StartActual
Apr 29, 2026
Primary completionEst.
Nov 10, 2028
CompletionEst.
Jan 9, 2029
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 22, 2026
Sites
1 site added — first site in France
Show site
  • Hôpital Claude Huriez - Service Oncologie · Lille, France
Oct 22, 2026
Start date
Apr 10, 2026→Apr 29, 2026 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in France
    Show site
    • Hôpital Claude Huriez - Service Oncologie · Lille, France
    Start date Apr 10, 2026→Apr 29, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06958224
Responsible party
Sponsor
First posted
May 6, 2025
Start date
Apr 29, 2026
Primary completion
Nov 10, 2028 (estimated)
Completion
Jan 9, 2029 (estimated)
Last update
Oct 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion